Articles Tagged with Xarelto injury lawyer

A Xarelto patient is fighting back against the reversal of a $28 million verdict against drug maker Johnson & Johnson (subsidiaries Bayer and Janssen), which she initially won for an alleged failure to warn against the heightened risk of internal bleeding. Xarelto injury

The verdict in Hartman et al v. Janssen Pharmaceuticals Inc., et al was reversed in January in state court, specifically the Philadelphia Court of Common Pleas. Even though jurors decided the case in favor of the plaintiff in December and awarded millions of dollars in damages, The Legal Intelligencer reports the judge granted the defense’s motion notwithstanding verdict. The decision was especially crushing because it was the first win for plaintiffs (albeit in state court) after four losses one after another in federal court.

Xarelto plaintiff’s appeal notes several challenges, including a remark by the judge indicating alleged “inflammatory” remarks by plaintiff council during closing arguments warranted a brand new trial. The judge reportedly made the statement during a post-trial hearing, following remarks by defense counsel asserting plaintiff’s attorney inappropriately referenced defendant manufacturers’ German ties by linking it with Nazis. However, that’s not exactly what the plaintiff’s attorney said. The closing argument did urge jurors to “swing the mighty sword of justice to let those folks know, in Berlin, Germany, when they sell their drugs to us Americans to make their billions,” that they must adequately label their medications. However, after the verdict, social media posts by several members of plaintiff’s trial team reportedly used the hashtag #killinnazis. That may not have been the wisest course of action, but as even the judge noted then, those posts would have had no way of influencing that verdict.  Continue reading

Drug companies are big multinational corporations for the most part, and as such report their profits and losses to Wall Street each quarter. That means these firms are very concerned about making money for their shareholders and their executives.  There is no question many medicines they make save a lot of lives. However, when the desire to rake in a profit overshadows the desire to keep people safe and healthy, problems arise.

white pillsOne of the drugs that makes a lot of money for Bayer AG is known as Xarelto.  Xarelto is part of a relatively new class of drugs called new oral anticoagulants (NOACs).  Xarelto is one NOAC manufactured by the German pharmaceutical giant and marketed by its partner in the U.S., Johnson & Johnson, but there other competitors. Those include Savaysa, Elliquis, and Pradaxa.  These drugs are not only competing with each other, but they are also competing with Warfarin (Coumadin).

A recent news article from Yahoo shows that Xarelto was helping drive company sales this past fiscal quarter.

Continue reading

According to a recent news article from the Cook County Record, a woman has just filed a lawsuit against Bayer and Johnson & Johnson/Janssen Pharmaceuticals, who are the makers and U.S. marketing partners of the New Oral Anticoagulant (NOAC) Xarelto.

whitepillsThis lawsuit alleges that, after taking Xarelto, she suffered serious physical injury.  She is alleging that the drug Xarelto was defectively designed, causing her to suffer these severe medical effects and that the companies failed to warn her of these known defects. Continue reading

According to a recent report from WebMD News, a recent study, which asserted both Xarelto and Pradaxa were superior to Warfarin, found that Xarelto poses a higher risk of serious internal bleeding disorders than its competitor, Pradaxa. The drugs at issue are part of a new class of anticoagulants known as New Oral Anticoagulants (NOACs).  Xarelto, Pradaxa, Eliquis, and Savaysa are the four NOACs approved by the United States Food and Drug Administration (FDA).

untitled-1238929-mThe risk of increased internal bleeding disorders for patients taking Xarelto over patients taking Pradaxa was seen in patients who suffer from a serious medical condition known as atrial fibrillation (Afib).  Afib, is characterized by an irregular heartbeat not caused by a heart valve defect.  If this sounds familiar to you even though you do not suffer from Afib, it might be because Saturday Night Live alumni actor Kevin Nealon appears in a commercial where he discusses his own struggles with Afib and how taking Xarelto has helped him to lead a normal life. Continue reading

According to a recent news article from the Louisiana Record, the surviving daughter of a man from Ohio claims that her father died as a result of complications due to taking Xarelto.  The complaint was filed on April 8, 2016 in a United States District Court.  Plaintiff filed the suit against Janssen, which is the marketing arm of Johnson & Johnson and the United States marketing partner for Xarelto.  The plaintiff also named Bayer, which is the German pharmaceutical giant that manufactures Xarelto.packofpills

The claims included in the complaint are for fraud, breach of an express or implied warranty, defective design, failure to warn of a known danger, wrongful death, and negligent misrepresentation.  Continue reading

Xarelto, Eliquis, Pradaxa, and the newly-marketed Savaysa are all members of a class of drugs known as New Oral Anticoagulants (NOACs). They are all advertised as a safer and easier to use alternative to Warfarin (Coumadin), which has been the long-standing drug prescribed to patients who suffer from an irregular heartbeat condition known as atrial fibrillation (Afib).

pills-1023897-mAfib patients require either a blood thinner like Warfarin or an oral anticoagulant like Xarelto to decrease the risk they will develop a serious clotting disorder.   If patient develops clots deep within the veins of his or her legs, which is known as deep vein thrombosis (DVT), the clots can break loose and travel to the lungs, where they can puncture the tissue, causing a potentially deadly condition known as pulmonary embolism (PE). The clots can also block blood flow to the brain, which results in a stroke. Continue reading

Contact Information